Compare · RCLF vs SYK
RCLF vs SYK
Side-by-side comparison of Rosecliff Acquisition Corp I (RCLF) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RCLF and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $93.70B, about 302.0x RCLF ($310.2M).
- SYK has hit the wire 5 times in the past 4 weeks while RCLF has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 0 for RCLF).
- Company
- Rosecliff Acquisition Corp I
- Stryker Corporation
- Price
- $11.50-8.40%
- $327.50-0.63%
- Market cap
- $310.2M
- $93.70B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Rosecliff Acquisition Corp I
Rosecliff Acquisition Corp I, a blank check company, focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization/similar business combination with one or more businesses. The company was incoporated in 2020 and is based in New York, New York.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest RCLF
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-8 filed by Rosecliff Acquisition Corp I
- SEC Form SC 13G filed by Rosecliff Acquisition Corp I
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Leadership Update
- SEC Form EFFECT filed by Rosecliff Acquisition Corp I
- SEC Form 424B3 filed by Rosecliff Acquisition Corp I
- SEC Form S-1/A filed by Rosecliff Acquisition Corp I (Amendment)
- SEC Form S-1 filed by Rosecliff Acquisition Corp I
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew